Loading...
•
Mar 31, 2021
Iovance Q1 2021 Earnings Report
Reported first quarter financial results and corporate updates.
Key Takeaways
Iovance Biotherapeutics reported its first quarter 2021 financial results, highlighting a net loss of $75.4 million, or $0.51 per share, and holding $610.2 million in cash, cash equivalents, investments and restricted cash.
Continued work on potency assays in support of a BLA for lifileucel.
Submitted additional potency assay data to the FDA.
Clinical data for TIL being presented at medical meetings, including data for TIL in combination with pembrolizumab in melanoma at ASCO.
Balance sheet strength positions Iovance to fulfill operating plan and advance pipeline.
Forward Guidance
Iovance anticipates that the year-end balance of cash, cash equivalents, investments and restricted cash will be sufficient into 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...